Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Key Sessions

Eric Elenko

Keynote Chat - Investing in Digital Innovation

PureTech Health

Oct 10
Show Filter
8:00am - 9:00am 60 mins
Registration and Networking Breakfast
9:00am - 9:15am 15 mins
Welcome & Opening Remarks
9:15am - 9:45am 30 mins
Market Outlook 2018: Where are We Now and Where are We Going?
  • Klaus Mendla, PhD - Global Head, Business Development and Licensing CNS, Boehringer Ingelheim International
  • Erika Smith - CEO, ReNetX Bio
  • Jonathan Savidge - CEO, Syndesi Therapeutics
  • Moderator Kiran Reddy - Venture Partner, Clarus Ventures

2017 Saw a wave of investment in Neuro and Neuro startups, while at the same time facing challenges in late stage financing and advancements in CNS disease treatment and drug development. Where is the landscape headed and how might the varying elements impacting the industry play out for those operating in the business of Neuro drug development? 

9:45am - 10:15am 30 mins
Keynote Chat - Investing in Digital Innovation
  • Eric Elenko - Chief of Research and Strategy, PureTech Health
  • Jim Harper - Co-Founder, Sonde Health

Sit in on an investor/founder origin story and Q&A session with an investor and founder of digital medicine company Sonde Health. 

10:15am - 10:45am 30 mins
Enhancing Reproducibility in Translational Research
  • Panelist Thomas Engber - SVP, Head of Pharmacology and Translation, Disarm Therapeutics
  • Panelist Marion Wittman - Vice President Biology, Praxis Precision Medicines
  • Moderator Judith Dunn - EIR, Atlas Venture

A discussion around not only the difficulties of validation, but how researchers might significantly "move the needle" in a meaningful way through best practices

10:45am - 11:15am 30 mins
Networking Break
11:15am - 11:30am 15 mins
Emerging Technology Show & Tell
  • Paul Pyzowski - Corporate Development, Neuroelectrics
  • Spyros Papapetropoulos - EVP, Head of R&D and CMO, Cavion
  • Jonathan Rubin - Chief Medical Officer, Atentiv

Sit in on a demo of gadgets and emerging tech with neuro implications

11:30am - 12:00pm 30 mins
Fireside Chat: Digital Health & Emerging Technology for CNS Indications
  • Panelist Paul Pyzowski - Corporate Development, Neuroelectrics
  • Panelist Eddie Martucci - Co-Founder and CEO; VP, Akili Interactive Labs; PureTech Health
  • Panelist Jonathan Rubin - Chief Medical Officer, Atentiv
  • Moderator Spyros Papapetropoulos - EVP, Head of R&D and CMO, Cavion

Continue the conversation with tech life sciences as they discuss how innovation in technological modalities can change the landscape for CNS indications 

12:00pm - 12:15pm 15 mins
Spotlight Focus: Voyager Therapeutics
  • Dinah Sah - CSO, Voyager Therapeutics
12:15pm - 12:45pm 30 mins
New Paradigms in Treating Neurodegenerative Disorders
  • Dinah Sah - CSO, Voyager Therapeutics
  • Martin Tolar, MD, Ph.D. - CEO, Alzheon
  • Carmela Abraham, Ph.D. - Founder, Klogene Therapeutics
  • Moderator Jonathan Lewis, MD, PhD - Executive Chairman and Chief Executive Officer, Samus Therapeutics

Is there a new paradigm of how we understand Neurodegeneration? What might it mean for future scientific advancement, treatment, and the patient ? 

12:45pm - 1:45pm 60 mins
Networking Lunch
1:45pm - 2:00pm 15 mins
Spotlight Focus: WaveLife Sciences
  • Speaker Paul Bolno - President & CEO, Wave Life Sciences

Learn how Wave Life Sciences, a clinical-stage genetics medicines company, is using its chemistry and stereochemistry platform to design nucleic acid therapeutics to address CNS and neuromuscular disorders such as Huntington’s disease, Duchenne muscular dystrophy, amyotrophic lateral sclerosis and frontotemporal dementia. The platform was developed to optimize the pharmacological profile of nucleic acids by maximizing therapeutic effect while minimizing the potential for side effects and safety risks. The company has three programs currently in clinical development.

2:00pm - 2:30pm 30 mins
Novel Therapeutic Approaches to Neuromuscular Diseases
  • Panelist Paul Bolno - President & CEO, Wave Life Sciences
  • Panelist David Giljohann - CEO, Exicure
  • Panelist Christine McSherry - Executive Director, Jett Foundation
  • Panelist Philippe Picaut - PhD - Senior Vice President of Neuroscience R&D, Ipsen

Explore recent regulatory developments in the space as well as how modalities like gene editing and other emerging treatments might change not only the therapeutic landscape, but the life of the patient

2:30pm - 3:00pm 30 mins
Addressing Neuroinflammation
  • Panelist Ole Isacson - Professor of Neurology, Harvard Medical School and Director of the Neuroregeneration Research Institute, McLean Hospital/Harvard Medical School
  • Panelist Roger Bullock - Chief Medical Officer, Oryzon Genomics
  • Panelist Barbara Wallner - Chief Scientific Officer, Samus Therapeutics
  • Moderator Alan Ezekowitz - President & CEO, Abide Therapeutics Inc.
3:00pm - 3:30pm 30 mins
Networking Break
3:30pm - 4:00pm 30 mins
Pain & Addiction
  • Panelist Randall Stevens - Chief Medical Officer, Centrexion Therapeutics Corp.
  • Panelist Anthony McKinney - Founder, President & CEO, Ethismos Research, Inc.
  • Moderator Mark Corrigan - Chairman of the Board, BlackThorn Therapeutics

How are companies addressing chronic pain management? Address how safety and efficacy challenges are being addressed in the development of therapeutics in this space

4:00pm - 4:15pm 15 mins
Spotlight: Highlighting New Treatments in Neuroscience
  • Leen Kawas - CEO & President, M3 Biotechnology, Inc.
4:15pm - 4:45pm 30 mins
Riding the Wave of Innovation: What Will Shape the Next 5-10 Years in Neuro?
  • Albert Robichaud - Chief Scientific Officer, Sage Therapeutics, Inc.
  • Thomas Large - CEO, Blue Oak Pharmaceuticals
  • Leen Kawas - CEO & President, M3 Biotechnology, Inc.

How might the convergence of early stage investment, emerging technology, data utilization and a patient-centric approach shape the trajectory of Neuro therapeutic development? 

4:45pm - 5:00pm 15 mins
Closing Remarks
5:00pm - 6:00pm 60 mins
Cocktails and Hors d'oeuvres